{"id":722132,"date":"2026-04-16T15:25:11","date_gmt":"2026-04-16T12:25:11","guid":{"rendered":"https:\/\/buradabiliyorum.com\/en\/cambridge-biotech-storm-therapeutics-raises-56m\/"},"modified":"2026-04-16T15:25:11","modified_gmt":"2026-04-16T12:25:11","slug":"cambridge-biotech-storm-therapeutics-raises-56m","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/cambridge-biotech-storm-therapeutics-raises-56m\/","title":{"rendered":"Cambridge biotech STORM Therapeutics raises $56M"},"content":{"rendered":"
\n

STC-15 is the world\u2019s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series<\/a> C is backed entirely by existing investors including Pfizer Ventures and M Ventures.<\/em><\/p>\n\n

STORM Therapeutics<\/span><\/a>, a Cambridge-based clinical-stage biotech targeting RNA modifications to treat cancer, has raised $56 million in a Series C round and dosed the first patient in a Phase 2 clinical trial of its lead drug, STC-15, in selected sarcoma indications. <\/span><\/p>\n

The round was funded entirely by existing investors: M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).<\/span><\/p>\n

STC-15 is a first-in-class, oral small-molecule inhibitor of METTL3 \u2013 an enzyme that methylates messenger RNA and plays a central role in cancer stem cell differentiation. It is the first RNA-modifying enzyme inhibitor ever to enter human clinical trials, having commenced its Phase 1 study in November 2022. <\/span><\/p>\n

\n
\n
<\/div>\n

<\/p>\n

\n

The \ud83d\udc9c of EU tech<\/p>\n

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!<\/p>\n<\/div>\n<\/div>\n<\/div>\n

METTL3 adds a chemical tag called m6A to mRNA, influencing how cells read genetic instructions; in certain cancers, this process is hijacked to keep malignant progenitor cells locked in a proliferative, undifferentiated state. Inhibiting METTL3 disrupts this process, pushing cancer cells towards cycle arrest and programmed death.<\/span><\/p>\n

Sarcomas, cancers arising from bone or soft tissue including muscle, fat, cartilage, and blood vessels, account for 1% of adult cancers and 15% of paediatric cancers. <\/span><\/p>\n

They are notoriously difficult to treat because they frequently lack the driver mutations or immunogenic features that make most solid tumours amenable to targeted therapy or immunotherapy. <\/span><\/p>\n

STORM\u2019s thesis is that sarcomas are particularly dependent on METTL3-driven mRNA methylation for their growth and survival, making them a biologically compelling target for STC-15. In Phase 1, the drug demonstrated durable tumour regression across multiple sarcoma subtypes across dose levels between 60mg and 200mg taken three times weekly. <\/span><\/p>\n

Full Phase 1 results are expected to be presented at a medical conference in 2026.<\/span><\/em><\/p>\n

The Phase 2 monotherapy trial is designed to support a potential accelerated regulatory app<\/a>roval pathway for STC-15, and to build a foundation for expanding clinical development into additional oncology indications. The first patient has now been successfully dosed. The trial\u2019s ClinicalTrials.gov identifier is <\/span>NCT06975293<\/span><\/a>. <\/span><\/p>\n

STC-15 is simultaneously being evaluated in a Phase 1b\/2 combination study with LOQTORZI (toripalimab), a PD-1 inhibitor from Coherus BioScience<\/a>s, across non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer, a collaboration announced in May 2025.\u00a0<\/span><\/p>\n

Jonathan Trent, MD of the University of Miami\u2019s Sylvester Comprehensive Cancer Center and a clinical investigator on the trial, said STC-15\u2019s mechanism \u201ctargets sarcomas at their vulnerability, reprogramming malignant cells toward cell cycle arrest and apoptosis.\u201d<\/em> <\/span><\/p>\n

STORM CEO Jerry McMahon described the Phase 2 dosing as \u201ca pivotal breakthrough in tackling cancers characterised by aberrant cell differentiation,\u201d pointing to the unmet need in sarcoma where existing options remain limited.<\/span><\/p>\n<\/p><\/div>\n

If you liked the article, do not forget to share it with your friends. Follow us on\u00a0Google News<\/a><\/span>\u00a0too, click on the star and choose us from your favorites.<\/span><\/strong><\/p><\/blockquote>\n

\n

If you want to read more like this article, you can visit our Technology category.<\/a><\/span><\/strong><\/p>\n<\/blockquote>\n

Source<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

STC-15 is the world\u2019s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Ventures. STORM Therapeutics, a Cambridge-based clinical-stage biotech targeting RNA modifications to treat cancer, has raised $56 million in…<\/p>\n","protected":false},"author":1,"featured_media":722133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cdn0.tnwcdn.com\/wp-content\/blogs.dir\/1\/files\/2026\/04\/STORM-Therapeutics.png","fifu_image_alt":"","footnotes":""},"categories":[18],"tags":[],"class_list":["post-722132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/722132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/comments?post=722132"}],"version-history":[{"count":0,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/posts\/722132\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media\/722133"}],"wp:attachment":[{"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/media?parent=722132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/categories?post=722132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/buradabiliyorum.com\/en\/wp-json\/wp\/v2\/tags?post=722132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}